Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW.
Revach OY, et al. Among authors: hacohen n.
bioRxiv [Preprint]. 2024 Mar 26:2024.02.12.579184. doi: 10.1101/2024.02.12.579184.
bioRxiv. 2024.
PMID: 38405985
Free PMC article.
Preprint.